KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$45.5 million.

  • Inovio Pharmaceuticals' Profit After Tax fell 8080.32% to -$45.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.1 million, marking a year-over-year increase of 418.97%. This contributed to the annual value of -$107.3 million for FY2024, which is 2058.75% up from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Profit After Tax stood at -$45.5 million for Q3 2025, which was down 8080.32% from -$23.5 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Profit After Tax registered a high of -$19.4 million during Q4 2024, and its lowest value of -$108.5 million during Q2 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' median Profit After Tax value was -$37.8 million (recorded in 2022), while the average stood at -$48.1 million.
  • In the last 5 years, Inovio Pharmaceuticals' Profit After Tax crashed by 41384.9% in 2021 and then skyrocketed by 6724.85% in 2023.
  • Inovio Pharmaceuticals' Profit After Tax (Quarter) stood at -$106.9 million in 2021, then skyrocketed by 49.07% to -$54.5 million in 2022, then surged by 54.09% to -$25.0 million in 2023, then grew by 22.3% to -$19.4 million in 2024, then crashed by 134.2% to -$45.5 million in 2025.
  • Its last three reported values are -$45.5 million in Q3 2025, -$23.5 million for Q2 2025, and -$19.7 million during Q1 2025.